IN2014MN02293A - - Google Patents

Info

Publication number
IN2014MN02293A
IN2014MN02293A IN2293MUN2014A IN2014MN02293A IN 2014MN02293 A IN2014MN02293 A IN 2014MN02293A IN 2293MUN2014 A IN2293MUN2014 A IN 2293MUN2014A IN 2014MN02293 A IN2014MN02293 A IN 2014MN02293A
Authority
IN
India
Prior art keywords
polypeptides
scfvs
antibody
antibodies
fragments
Prior art date
Application number
Other languages
English (en)
Inventor
Philip Huat Tan
Sateesh Kumar Natarajan
Catherine J Mcmahan
Original Assignee
Emergent Product Dev Seattle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Seattle filed Critical Emergent Product Dev Seattle
Publication of IN2014MN02293A publication Critical patent/IN2014MN02293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN2293MUN2014 2012-04-20 2013-04-18 IN2014MN02293A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261636557P 2012-04-20 2012-04-20
US201261718635P 2012-10-25 2012-10-25
US201361799849P 2013-03-15 2013-03-15
PCT/US2013/037135 WO2013158856A2 (en) 2012-04-20 2013-04-18 Cd3 binding polypeptides

Publications (1)

Publication Number Publication Date
IN2014MN02293A true IN2014MN02293A (cg-RX-API-DMAC7.html) 2015-08-07

Family

ID=49384230

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2293MUN2014 IN2014MN02293A (cg-RX-API-DMAC7.html) 2012-04-20 2013-04-18

Country Status (16)

Country Link
US (1) US10202452B2 (cg-RX-API-DMAC7.html)
EP (1) EP2839019A4 (cg-RX-API-DMAC7.html)
JP (2) JP6509724B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150004856A (cg-RX-API-DMAC7.html)
CN (1) CN104487587A (cg-RX-API-DMAC7.html)
AU (2) AU2013249267A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014025830A8 (cg-RX-API-DMAC7.html)
CA (1) CA2870545A1 (cg-RX-API-DMAC7.html)
HK (2) HK1207398A1 (cg-RX-API-DMAC7.html)
IL (1) IL235093B (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02293A (cg-RX-API-DMAC7.html)
MX (1) MX366813B (cg-RX-API-DMAC7.html)
RU (1) RU2673153C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201608307WA (cg-RX-API-DMAC7.html)
UA (1) UA119227C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013158856A2 (cg-RX-API-DMAC7.html)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
ES2693232T3 (es) 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Agente terapéutico que induce citotoxicidad
CA2833019A1 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
MX366813B (es) 2012-04-20 2019-07-25 Aptevo Res & Development Llc Polipeptidos de enlace cd3.
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
EP3096789B1 (en) 2014-01-24 2020-10-28 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Antibodies against f glycoprotein of hendra and nipah viruses
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MY202412A (en) 2015-01-23 2024-04-27 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2016248947B2 (en) 2015-04-13 2020-07-16 Pfizer Inc. Chimeric Antigen Receptors targeting B-Cell Maturation Antigen
SG10201912823PA (en) 2015-04-13 2020-02-27 Pfizer Therapeutic antibodies and their uses
RU2754661C2 (ru) 2015-05-01 2021-09-06 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Гликанзависимые иммунотерапевтические молекулы
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN104892765B (zh) * 2015-06-29 2018-04-10 深圳市国创纳米抗体技术有限公司 一种抗CD3抗原和Her‑2抗原的双特异性抗体
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
JP2018536389A (ja) * 2015-10-02 2018-12-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト メソテリンとｃｄ３に結合する二重特異性細胞活性化抗原結合分子
MX2018005229A (es) 2015-12-09 2019-04-29 F Hoffmann­La Roche Ag Anticuerpo anti-cd20 de tipo ii y usos del mismo.
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11339225B2 (en) * 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN107365387B (zh) * 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017268460B2 (en) 2016-05-20 2023-12-14 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
HUE072731T2 (hu) * 2016-05-20 2025-12-28 Harpoon Therapeutics Inc Egyszeres láncú variábilis fragmentumú CD3-kötõ proteinek
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN106117358A (zh) * 2016-06-16 2016-11-16 中山大学 抗cd3单域抗体
CN106117360A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106117361A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106146661A (zh) * 2016-06-17 2016-11-23 中山大学 抗cd3单域抗体
CN106084047A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106084046A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106117359A (zh) * 2016-06-17 2016-11-16 中山大学 抗cd3单域抗体
CN106084048A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
CN106084049A (zh) * 2016-06-17 2016-11-09 中山大学 抗cd3单域抗体
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
CN106146662A (zh) * 2016-07-18 2016-11-23 中山大学 抗cd3单域抗体
SI4050034T1 (sl) 2016-09-14 2024-07-31 Teneoone, Inc. Protitelesa, ki se vežejo na CD3
UA127450C2 (uk) 2016-09-21 2023-08-30 Аптево Рісьорч Енд Дівелопмент Елелсі Рекомбінантний поліпептид, що зв'язується з cd123
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
MX2019015563A (es) 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
LT3694529T (lt) 2017-10-13 2024-10-10 Harpoon Therapeutics, Inc. Trispecifiniai baltymai ir panaudojimo būdai
TW202428622A (zh) 2017-10-18 2024-07-16 瑞士商諾華公司 用於選擇性蛋白質降解的組合物及方法
BR112020009336A2 (pt) 2017-11-15 2020-10-27 Novartis Ag receptor quimérico de antígenos de alvejamento de bcma, receptor quimérico de antígenos de alvejamento de cd19 e terapias de combinação
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
JP7486421B2 (ja) 2017-12-22 2024-05-17 テネオバイオ， インコーポレイテッド Ｃｄ２２に結合する重鎖抗体
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
JP2021523192A (ja) 2018-05-14 2021-09-02 ハープーン セラピューティクス，インク． 免疫グロブリン分子の条件的活性化のための結合部分
CN112533950B (zh) * 2018-06-29 2023-03-10 多玛医药科技(苏州)有限公司 抗CD3e抗体及其用途
MY208638A (en) 2018-07-02 2025-05-21 Amgen Inc Anti-steap1 antigen-binding protein
EP3844267B1 (en) 2018-08-31 2025-06-25 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
IL281413B2 (en) * 2018-09-19 2024-09-01 Fujifilm Cellular Dynamics Inc Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US12258405B2 (en) * 2018-12-07 2025-03-25 Jiangsu Hengrui Medicine Co., Ltd. CD3 antibody and pharmaceutical use thereof
EP3928790A4 (en) * 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen binding fragment and application thereof
AU2020229806A1 (en) 2019-02-25 2021-07-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
UA128906C2 (uk) 2019-06-14 2024-11-20 Тенеобіо, Інк. Поліспецифічні антитіла, що містять тільки важкі ланцюги, які зв'язуються з cd22 та cd3
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
CN118562007A (zh) * 2019-12-19 2024-08-30 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
US20230151102A1 (en) 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
KR20220127843A (ko) 2020-01-13 2022-09-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 단백질 치료제용 제형
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
US12435155B2 (en) 2020-02-21 2025-10-07 Macrogenics, Inc. CD137 binding molecules and uses thereof
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
CA3218661A1 (en) 2020-04-04 2022-11-17 David Campbell Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
MX2023000839A (es) * 2020-07-20 2023-04-18 Zymeworks Bc Inc Proteinas de fusion que comprenden un par ligando-receptor y una proteina biologicamente funcional.
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
JP2023545057A (ja) * 2020-10-07 2023-10-26 ドレン バイオ， インコーポレイテッド 抗デクチン－１抗体及びその使用方法
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
US20240209116A1 (en) * 2021-04-28 2024-06-27 Ngm Biopharmaceuticals, Inc. Multimerization of binding molecules having an antibody constant region variant
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
JP2024517535A (ja) 2021-04-30 2024-04-23 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と抗ｃｄ７９ｂ抗体薬物コンジュゲートを用いた併用治療の投与
WO2022240865A1 (en) * 2021-05-11 2022-11-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
AU2022276523A1 (en) 2021-05-21 2024-01-18 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
IL312503A (en) 2021-11-03 2024-07-01 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
AU2023238766A1 (en) 2022-03-23 2024-07-25 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
CN115029318B (zh) * 2022-05-12 2022-12-20 成都赋智健康科技有限公司 携带多特异性抗体基因的间充质干细胞及其制药用途
CN115232213B (zh) * 2022-07-19 2025-08-15 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO1998003670A1 (en) 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
AU2719099A (en) 1998-01-23 1999-08-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Multipurpose antibody derivatives
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU2002226930A1 (en) * 2000-11-17 2002-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
RU2179862C1 (ru) 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2316951A1 (en) 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040044182A1 (en) 2001-09-17 2004-03-04 Hunt Joan S Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
JP4762158B2 (ja) 2004-02-16 2011-08-31 ミクロメット・アクチェンゲゼルシャフト 低い免疫原性を有する結合分子
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
ES2616316T3 (es) 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
KR101463631B1 (ko) * 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
AU2007258694B2 (en) 2006-06-06 2011-12-22 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2089431A4 (en) 2006-10-19 2010-03-17 Tolerx Inc METHOD AND COMPOSITIONS FOR EFFICIENT REMOVAL OF PROTEIN A FROM BINDING MOLECULE PREPARATION
CA2673470A1 (en) 2006-12-21 2008-07-03 Macrogenics, Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2310410A2 (en) 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tnf- antagonist multi-target binding proteins
JP2011526794A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＧＦ−βアンタゴニスト多重標的結合性分子
AU2009266856A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc IL6 immunotherapeutics
WO2010014629A1 (en) 2008-07-28 2010-02-04 Trubion Pharmaceuticals, Inc. Multi-specific binding proteins targeting b cell disorders
KR20110047255A (ko) 2008-09-26 2011-05-06 로슈 글리카트 아게 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
CA2739460C (en) 2008-10-02 2019-05-21 Emergent Product Development Seattle, Llc Cd86 antagonist multi-target binding proteins
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
NZ603623A (en) * 2008-10-10 2014-05-30 Emergent Product Dev Seattle Tcr complex immunotherapeutics
MX2011011925A (es) 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
MX341796B (es) 2009-12-29 2016-09-02 Emergent Product Dev Seattle Proteinas de union heterodimericas y usos de las mismas.
CA2833019A1 (en) * 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
KR101308922B1 (ko) * 2012-02-15 2013-09-23 주식회사 경동나비엔 연소기기용 듀얼 벤츄리
MX366813B (es) 2012-04-20 2019-07-25 Aptevo Res & Development Llc Polipeptidos de enlace cd3.

Also Published As

Publication number Publication date
AU2017228643B2 (en) 2019-12-05
UA119227C2 (uk) 2019-05-27
HK1207398A1 (en) 2016-01-29
CN104487587A (zh) 2015-04-01
BR112014025830A8 (pt) 2017-10-10
MX366813B (es) 2019-07-25
AU2017228643A1 (en) 2017-10-05
EP2839019A2 (en) 2015-02-25
US10202452B2 (en) 2019-02-12
JP2015521032A (ja) 2015-07-27
WO2013158856A2 (en) 2013-10-24
CA2870545A1 (en) 2013-10-24
JP2018138039A (ja) 2018-09-06
RU2014142166A (ru) 2016-06-10
SG11201406346SA (en) 2014-11-27
SG10201608307WA (en) 2016-11-29
KR20150004856A (ko) 2015-01-13
US20150232557A1 (en) 2015-08-20
IL235093A0 (en) 2014-12-31
HK1208707A1 (en) 2016-03-11
RU2673153C2 (ru) 2018-11-22
MX2014012578A (es) 2015-05-11
EP2839019A4 (en) 2016-03-30
BR112014025830A2 (cg-RX-API-DMAC7.html) 2017-06-20
IL235093B (en) 2019-09-26
AU2013249267A1 (en) 2014-10-23
JP6509724B2 (ja) 2019-05-08

Similar Documents

Publication Publication Date Title
IN2014MN02293A (cg-RX-API-DMAC7.html)
MX2021009151A (es) Anticuerpos y receptores de antigeno quimerico especificos para ror1.
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
PH12018501080A1 (en) Pd1 and/or lag3 binders
NZ706232A (en) Anti-cd3 antibodies and uses thereof
WO2012135854A3 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
PH12018501079A1 (en) Ctla4 binders
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
MX2021001711A (es) Proteínas biespecíficas modificadas.
HK1251480A1 (zh) Cd3结合多肽
WO2015150526A3 (en) Cd33 specific chimeric antigen receptors for cancer immunotherapy
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
MX2013011176A (es) Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento.
MX382398B (es) Proteinas de union a antigeno st2.
MY176294A (en) Antibodies comprising chimeric constant domains
WO2012017082A3 (de) Anti-la antikörper und ihre anwendung zum immunotargeting
GB201212940D0 (en) Antibodies to highly conserved targets
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
WO2011085165A3 (en) Ca-125 immune complexes as biomarkers of ovarian cancer
EP4268848A3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy